Selected research
Industry Research
Transdermal Drug Industry Research Report 2026
Market perspective
The global Transdermal Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Transdermal Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Transdermal Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Transdermal Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Transdermal Drug include Johnson & Johnson, Novartis, Mylan, GSK, Beijing Tide Pharmaceutical, Bayer, UCB Pharma, Teva Pharmaceutical and Nitto Denko, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Transdermal Drug market in terms of revenue (US$ million) and, where applicable, sales volume (M Pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/M Pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Transdermal Drug Market by Company
Johnson & Johnson
Novartis
Mylan
GSK
Beijing Tide Pharmaceutical
Bayer
UCB Pharma
Teva Pharmaceutical
Nitto Denko
Mundipharma
Luye Pharma Group
IBSA Group
Hisamitsu Pharmaceutical
Grünenthal
Dr Reddy’s Laboratories
Chattem
Transdermal Drug Segment by Type
Methyl Salicylate-based Patch
Diclofenac Patch
Nicotine Transdermal Patch
Lidocaine Patch
Rivastigmine Transdermal Patch
Fentanyl Transdermal Patch
Others
Transdermal Drug Segment by Application
Rx Channel
OTC Channel
Transdermal Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transdermal Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Transdermal Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transdermal Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Transdermal Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Transdermal Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Transdermal Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Methyl Salicylate-based Patch
- Diclofenac Patch
- Nicotine Transdermal Patch
- Lidocaine Patch
- Rivastigmine Transdermal Patch
- Fentanyl Transdermal Patch
- Others
Applications
- Rx Channel
- OTC Channel
Companies covered
- Johnson & Johnson
- Novartis
- Mylan
- GSK
- Beijing Tide Pharmaceutical
- Bayer
- UCB Pharma
- Teva Pharmaceutical
- Nitto Denko
- Mundipharma
- Luye Pharma Group
- IBSA Group
- Hisamitsu Pharmaceutical
- Grünenthal
- Dr Reddy’s Laboratories
- Chattem
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Transdermal Drug Market Size (2021-2032)
- 2.2.2 Global Transdermal Drug Sales (2021-2032)
- 2.2.3 Global Transdermal Drug Market Average Price (2021-2032)
- 2.3 Transdermal Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Methyl Salicylate-based Patch
- 2.3.3 Diclofenac Patch
- 2.3.4 Nicotine Transdermal Patch
- 2.3.5 Lidocaine Patch
- 2.3.6 Rivastigmine Transdermal Patch
- 2.3.7 Fentanyl Transdermal Patch
- 2.3.8 Others
- 2.4 Transdermal Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Rx Channel
- 2.4.3 OTC Channel
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Transdermal Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Transdermal Drug Sales (M Pcs) of Manufacturers (2021-2026)
- 3.3 Global Transdermal Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Transdermal Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Transdermal Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Transdermal Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Transdermal Drug, Product Type & Application
- 3.8 Global Manufacturers of Transdermal Drug, Established Date
- 3.9 Global Transdermal Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Johnson & Johnson
- 4.1.1 Johnson & Johnson Company Information
- 4.1.2 Johnson & Johnson Business Overview
- 4.1.3 Johnson & Johnson Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Johnson & Johnson Transdermal Drug Product Portfolio
- 4.1.5 Johnson & Johnson Recent Developments
- 4.2 Novartis
- 4.2.1 Novartis Company Information
- 4.2.2 Novartis Business Overview
- 4.2.3 Novartis Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis Transdermal Drug Product Portfolio
- 4.2.5 Novartis Recent Developments
- 4.3 Mylan
- 4.3.1 Mylan Company Information
- 4.3.2 Mylan Business Overview
- 4.3.3 Mylan Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Mylan Transdermal Drug Product Portfolio
- 4.3.5 Mylan Recent Developments
- 4.4 GSK
- 4.4.1 GSK Company Information
- 4.4.2 GSK Business Overview
- 4.4.3 GSK Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 GSK Transdermal Drug Product Portfolio
- 4.4.5 GSK Recent Developments
- 4.5 Beijing Tide Pharmaceutical
- 4.5.1 Beijing Tide Pharmaceutical Company Information
- 4.5.2 Beijing Tide Pharmaceutical Business Overview
- 4.5.3 Beijing Tide Pharmaceutical Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Beijing Tide Pharmaceutical Transdermal Drug Product Portfolio
- 4.5.5 Beijing Tide Pharmaceutical Recent Developments
- 4.6 Bayer
- 4.6.1 Bayer Company Information
- 4.6.2 Bayer Business Overview
- 4.6.3 Bayer Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bayer Transdermal Drug Product Portfolio
- 4.6.5 Bayer Recent Developments
- 4.7 UCB Pharma
- 4.7.1 UCB Pharma Company Information
- 4.7.2 UCB Pharma Business Overview
- 4.7.3 UCB Pharma Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 UCB Pharma Transdermal Drug Product Portfolio
- 4.7.5 UCB Pharma Recent Developments
- 4.8 Teva Pharmaceutical
- 4.8.1 Teva Pharmaceutical Company Information
- 4.8.2 Teva Pharmaceutical Business Overview
- 4.8.3 Teva Pharmaceutical Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Teva Pharmaceutical Transdermal Drug Product Portfolio
- 4.8.5 Teva Pharmaceutical Recent Developments
- 4.9 Nitto Denko
- 4.9.1 Nitto Denko Company Information
- 4.9.2 Nitto Denko Business Overview
- 4.9.3 Nitto Denko Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Nitto Denko Transdermal Drug Product Portfolio
- 4.9.5 Nitto Denko Recent Developments
- 4.10 Mundipharma
- 4.10.1 Mundipharma Company Information
- 4.10.2 Mundipharma Business Overview
- 4.10.3 Mundipharma Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Mundipharma Transdermal Drug Product Portfolio
- 4.10.5 Mundipharma Recent Developments
- 4.11 Luye Pharma Group
- 4.11.1 Luye Pharma Group Company Information
- 4.11.2 Luye Pharma Group Business Overview
- 4.11.3 Luye Pharma Group Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Luye Pharma Group Transdermal Drug Product Portfolio
- 4.11.5 Luye Pharma Group Recent Developments
- 4.12 IBSA Group
- 4.12.1 IBSA Group Company Information
- 4.12.2 IBSA Group Business Overview
- 4.12.3 IBSA Group Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 IBSA Group Transdermal Drug Product Portfolio
- 4.12.5 IBSA Group Recent Developments
- 4.13 Hisamitsu Pharmaceutical
- 4.13.1 Hisamitsu Pharmaceutical Company Information
- 4.13.2 Hisamitsu Pharmaceutical Business Overview
- 4.13.3 Hisamitsu Pharmaceutical Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Hisamitsu Pharmaceutical Transdermal Drug Product Portfolio
- 4.13.5 Hisamitsu Pharmaceutical Recent Developments
- 4.14 Grünenthal
- 4.14.1 Grünenthal Company Information
- 4.14.2 Grünenthal Business Overview
- 4.14.3 Grünenthal Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Grünenthal Transdermal Drug Product Portfolio
- 4.14.5 Grünenthal Recent Developments
- 4.15 Dr Reddy’s Laboratories
- 4.15.1 Dr Reddy’s Laboratories Company Information
- 4.15.2 Dr Reddy’s Laboratories Business Overview
- 4.15.3 Dr Reddy’s Laboratories Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Dr Reddy’s Laboratories Transdermal Drug Product Portfolio
- 4.15.5 Dr Reddy’s Laboratories Recent Developments
- 4.16 Chattem
- 4.16.1 Chattem Company Information
- 4.16.2 Chattem Business Overview
- 4.16.3 Chattem Transdermal Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Chattem Transdermal Drug Product Portfolio
- 4.16.5 Chattem Recent Developments
5 Global Transdermal Drug Market Scenario by Region
- 5.1 Global Transdermal Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Transdermal Drug Sales by Region: 2021-2032
- 5.2.1 Global Transdermal Drug Sales by Region: 2021-2026
- 5.2.2 Global Transdermal Drug Sales by Region: 2027-2032
- 5.3 Global Transdermal Drug Revenue by Region: 2021-2032
- 5.3.1 Global Transdermal Drug Revenue by Region: 2021-2026
- 5.3.2 Global Transdermal Drug Revenue by Region: 2027-2032
- 5.4 North America Transdermal Drug Market Facts & Figures by Country
- 5.4.1 North America Transdermal Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Transdermal Drug Sales by Country (2021-2032)
- 5.4.3 North America Transdermal Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Transdermal Drug Market Facts & Figures by Country
- 5.5.1 Europe Transdermal Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Transdermal Drug Sales by Country (2021-2032)
- 5.5.3 Europe Transdermal Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Transdermal Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Transdermal Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Transdermal Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Transdermal Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Transdermal Drug Market Facts & Figures by Country
- 5.7.1 South America Transdermal Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Transdermal Drug Sales by Country (2021-2032)
- 5.7.3 South America Transdermal Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Transdermal Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Transdermal Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Transdermal Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Transdermal Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Transdermal Drug Sales by Type (2021-2032)
- 6.1.1 Global Transdermal Drug Sales by Type (2021-2032) & (M Pcs)
- 6.1.2 Global Transdermal Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Transdermal Drug Revenue by Type (2021-2032)
- 6.2.1 Global Transdermal Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Transdermal Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Transdermal Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Transdermal Drug Sales by Application (2021-2032)
- 7.1.1 Global Transdermal Drug Sales by Application (2021-2032) & (M Pcs)
- 7.1.2 Global Transdermal Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Transdermal Drug Revenue by Application (2021-2032)
- 7.2.1 Global Transdermal Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Transdermal Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Transdermal Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Transdermal Drug Value Chain Analysis
- 8.1.1 Transdermal Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Transdermal Drug Production Mode & Process
- 8.2 Transdermal Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Transdermal Drug Distributors
- 8.2.3 Transdermal Drug Customers
9 Global Transdermal Drug Analyzing Market Dynamics
- 9.1 Transdermal Drug Industry Trends
- 9.2 Transdermal Drug Industry Drivers
- 9.3 Transdermal Drug Industry Opportunities and Challenges
- 9.4 Transdermal Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst